title: Sequence variants of estrogen receptor beta and risk of prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium.
abstract: BACKGROUND
  Estrogen receptor beta (ESR2) may play a role in modulating prostate carcinogenesis through the regulation of genes related to cell proliferation and apoptosis.
  
  
  METHODS
  We conducted nested case-control studies in the Breast and Prostate Cancer Cohort Consortium (BPC3) that pooled 8,323 prostate cancer cases and 9,412 controls from seven cohorts. Whites were the predominant ethnic group. We characterized genetic variation in ESR2 by resequencing exons in 190 breast and prostate cancer cases and genotyping a dense set of single nucleotide polymorphisms (SNP) spanning the locus in a multiethnic panel of 349 cancer-free subjects. We selected four haplotype-tagging SNPs (htSNP) to capture common ESR2 variation in Whites; these htSNPs were then genotyped in all cohorts. Conditional logistic regression models were used to assess the association between sequence variants of ESR2 and the risk of prostate cancer. We also investigated the effect modification by age, body mass index, and family history, as well as the association between sequence variants of ESR2 and advanced-stage (>or=T3b, N1, or M1) and high-grade (Gleason sum >or=8) prostate cancer, respectively.
  
  
  RESULTS
  The four tag SNPs in ESR2 were not significantly associated with prostate cancer risk, individually. The global test for the influence of any haplotype on the risk of prostate cancer was not significant (P = 0.31). However, we observed that men carrying two copies of one of the variant haplotypes (TACC) had a 1.46-fold increased risk of prostate cancer (99% confidence interval, 1.06-2.01) compared with men carrying zero copies of this variant haplotype. No SNPs or haplotypes were associated with advanced stage or high grade of prostate cancer.
  
  
  CONCLUSIONS
  In our analysis focused on genetic variation common in Whites, we observed little evidence for any substantial association of inherited variation in ESR2 with risk of prostate cancer. A nominally significant (P < 0.01) association between the TACC haplotype and prostate cancer risk under the recessive model could be a chance finding and, in any event, would seem to contribute only slightly to the overall burden of prostate cancer.
authors.affiliation: Channing Laboratory, 181 Longwood Avenue, Boston, MA 02115, USA. karen.chen@channing.harvard.edu
authors.forename: Yen-Ching
authors.initials: YC
authors.lastname: Chen
authors.forename: Peter
authors.initials: P
authors.lastname: Kraft
authors.forename: Philip
authors.initials: P
authors.lastname: Bretsky
authors.forename: Shamika
authors.initials: S
authors.lastname: Ketkar
authors.forename: David J
authors.initials: DJ
authors.lastname: Hunter
authors.forename: Demetrius
authors.initials: D
authors.lastname: Albanes
authors.forename: David
authors.initials: D
authors.lastname: Altshuler
authors.forename: Gerald
authors.initials: G
authors.lastname: Andriole
authors.forename: Christine D
authors.initials: CD
authors.lastname: Berg
authors.forename: Heiner
authors.initials: H
authors.lastname: Boeing
authors.forename: Noel
authors.initials: N
authors.lastname: Burtt
authors.forename: Bas
authors.initials: B
authors.lastname: Bueno-de-Mesquita
authors.forename: Howard
authors.initials: H
authors.lastname: Cann
authors.forename: Federico
authors.initials: F
authors.lastname: Canzian
authors.forename: Stephen
authors.initials: S
authors.lastname: Chanock
authors.forename: Alison
authors.initials: A
authors.lastname: Dunning
authors.forename: Heather S
authors.initials: HS
authors.lastname: Feigelson
authors.forename: Matthew
authors.initials: M
authors.lastname: Freedman
authors.forename: J Michael
authors.initials: JM
authors.lastname: Gaziano
authors.forename: Edward
authors.initials: E
authors.lastname: Giovannucci
authors.forename: Maria-Jose
authors.initials: MJ
authors.lastname: Sánchez
authors.forename: Christopher A
authors.initials: CA
authors.lastname: Haiman
authors.forename: Göran
authors.initials: G
authors.lastname: Hallmans
authors.forename: Richard B
authors.initials: RB
authors.lastname: Hayes
authors.forename: Brian E
authors.initials: BE
authors.lastname: Henderson
authors.forename: Joel
authors.initials: J
authors.lastname: Hirschhorn
authors.forename: Rudolf
authors.initials: R
authors.lastname: Kaaks
authors.forename: Timothy J
authors.initials: TJ
authors.lastname: Key
authors.forename: Laurence N
authors.initials: LN
authors.lastname: Kolonel
authors.forename: Loic
authors.initials: L
authors.lastname: LeMarchand
authors.forename: Jing
authors.initials: J
authors.lastname: Ma
authors.forename: Kim
authors.initials: K
authors.lastname: Overvad
authors.forename: Domenico
authors.initials: D
authors.lastname: Palli
authors.forename: Paul
authors.initials: P
authors.lastname: Pharaoh
authors.forename: Malcolm
authors.initials: M
authors.lastname: Pike
authors.forename: Eliot
authors.initials: E
authors.lastname: Riboli
authors.forename: Carmen
authors.initials: C
authors.lastname: Rodriguez
authors.forename: V Wendy
authors.initials: VW
authors.lastname: Setiawan
authors.forename: Meir
authors.initials: M
authors.lastname: Stampfer
authors.forename: Daniel O
authors.initials: DO
authors.lastname: Stram
authors.forename: Gilles
authors.initials: G
authors.lastname: Thomas
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Thun
authors.forename: Ruth C
authors.initials: RC
authors.lastname: Travis
authors.forename: Jarmo
authors.initials: J
authors.lastname: Virtamo
authors.forename: Antonia
authors.initials: A
authors.lastname: Trichopoulou
authors.forename: Sholom
authors.initials: S
authors.lastname: Wacholder
authors.forename: Stephanie J
authors.initials: SJ
authors.lastname: Weinstein
mesh_terms: D000368:Aged; D001943:Breast Neoplasms / Q000235:genetics* / Q000473:pathology; D016022:Case-Control Studies; D015331:Cohort Studies; D047629:Estrogen Receptor beta / Q000235:genetics*; D005091:Exons / Q000235:genetics; D005260:Female; D020022:Genetic Predisposition to Disease / Q000235:genetics*; D014644:Genetic Variation / Q000235:genetics*; D005838:Genotype; D006239:Haplotypes; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D020641:Polymorphism, Single Nucleotide / Q000235:genetics; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000473:pathology; D018570:Risk Assessment; D017422:Sequence Analysis, DNA / Q000379:methods*
chemical_list: D047629:Estrogen Receptor beta